Patent · US Active

Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor

US11413282B2 · kind B2 · utility

3Cited by

7References

10Claims

0Family size

Assignees

Genentech, Inc. · US
Hoffmann-La Roche Inc. · US
Abb Vie Inc. · US

Inventors

Deepak Sampath · South San Francisco, US
Christian Klein · Iffeldorf, DE
Wayne Fairbrother · South San Francisco, US

Key dates

Filing date	Nov 30, 2016
Grant date	Aug 16, 2022
Priority date	—
Expiry date	Nov 30, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/73
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.